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Abstract: G-protein coupled receptors (GPCRs) represent important targets for drug 
discovery because they participate in a wide range of cellular signalling pathways 
that play a role in a variety of pathological conditions. The characterization of the 
patho-physiological profile and functional roles of new receptors is highly 
dependent on the availability of potent and selective ligands and new screening 
assays. The study of the pharmacological profile of new chemical entities is very 
important in order to predict the activity of drugs and their clinical adverse effect in 
humans. In the last decade, a large number of new in vitro radiolabel-free assays 
were developed and relevant information on diseases was upgraded. In particular, 
radiolabel-free assays led significant easy to handle and safer tools for operators. 
The aim of this review is to analyze these assays in terms of new drug activity and toxicology prediction 
and translation of non-clinical findings to humans in order to provide a powerful tool to aid drug 
development. 
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1. INTRODUCTION 
 From many years, G-protein coupled receptors (GPCRs) 
were used as targets for drug discovery and the presence of 
new drugs commercially available that interact with them 
was very important. In the last years, only few new drugs 
were available, but now the possibility to use high-
throughput approaches for GPCRs and the molecular 
modeling studies coupled with medicinal chemistry are 
giving new input to the search in this field. In fact, the 
availability of new technologies and approaches to screen 
GPCRs in combination with a genomically complete GPCRs 
target palette has allowed identifying targeted drugs with a 
specific therapeutic effect. Nevertheless, the major reasons 
that induce the failure of a drug development from the 
preclinical to clinical phases are the absence or the decrease 
of effect, the bioavailability and the toxicity of these drugs. 
Therefore, one of the most important steps in developing a 
new drug is the target identification and validation [1]. Drug 
development in the early stages was based on a series of in 
vitro screening planned to support the determination of 
effect, uptake, metabolism, and excretion of a drug, as well 
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as the detection of potential undesired effects. At the same 
time, the animal experimentation, driven by public opinion 
and by scientific and technological developments in 
toxicology, should be decreased. For these reasons, it is very 
important to search new in vitro technologies in order to 
know the effects of chemical entities minimizing the use of 
laboratory animals. The government agencies for the drug 
marketing, such as the National Institute of Environmental 
Health Sciences (NIEHS/NTP) or the Food and Drug 
Administration (FDA), are carefully considering the in vitro 
assays for xenobiotic toxicity to better assess human risks. It 
is very important to underline that some particular in vitro 
tests, that allow the understanding of drug human-specific 
toxicant activities, are based on the use of human cells and 
tissues [2]. Efforts in this direction have been made by the 
researchers in order to reduce the use of laboratory animals 
and, at the same time, to reduce risks to human health, since 
the results of in vivo experiments are often not sufficiently 
reliable in the view of the fact that there are differences 
between animals and humans. In vitro toxicity testing assays 
can be cheaper and quicker, as well as more useful than the 
traditional in vivo ones. Nevertheless, it is of great 
importance to pay scrupulous attention to the adaptations 
from in vitro to in vivo and this represents one of the major 
problems in this research field. Due to regulatory limitations 
and ethical considerations, the request of alternatives to 
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animal testing has gained a new impetus [3]. In vitro assays 
detect early indicators of what may ultimately lead to a good 
or an adverse health effects. They provide information about 
the “mechanism of action” by which a potential drug may 
revolutionize the pathology or physiology. These changes 
cannot be easily detected or measured using traditional tests, 
which are more focused on determining whether a particular 
drug dose produces an observable change in the health or 
normal functioning of the whole animal.  
 The in vitro tests are divided in two types of assays: 
acellular and cellular. More in detail in a cellular assay using 
the whole cell or a cell populations, the drug, at a particular 
dose, is positioned in contact to the cell culture and then the 
effect of the drug is evaluated. In this way, it is possible to 
estimate both a particular biological effect and the toxicity of 
a drug. Many methods allow this evaluation in particular in 
the last decade. 
2. ACELLULAR ASSAYS  
 Assays that utilize cells component instead of intact cell 
are called acellular assays. Moreover, often in these assays 
could be used often molecules extracted from cells, such as 
enzymes or DNA, correlated to the activation of one GPCR. 
This type of assay was mainly used to study the binding 
between the molecule and the GPCR using electrochemical 
or fluorescence methods. These kind of assays are called 
"mix-and-measure" assays because they do not require 
separation of bound ligands [4]. 
 Ligand binding assays provide a measure of the 
interactions that occur between two molecules, such as 
protein-bindings, and are used to study human body’s 
endogenous receptors, hormones, and other neurotransmitters 
in order to create drugs that are selective versus a particular 
target and that can antagonize or mimic the endogenous 
molecules [5]. Such progresses provide researchers the 
ability to detect the ligand and ligand-receptors, and to 
acquire important pharmacological information useful in 
drug development and treatment strategies [6]. 
 In the past, researchers used mainly radioactive assays 
but today, also to protect the human health and the 
environment, they have turned to non-radioactive assays and 
in this review it will report some of them. The non-
radioactive methods include, but are not limited to, time-
resolved fluorescence (TRF), fluorescence polarization (FP), 
fluorescence resonance energy transfer (FRET), and surface 
plasmon resonance (SPR) [7]. 
2.1. Time-resolved Fluorescence Assay  
 Until now, guanosine triphosphate (GTP) binding assays 
are performed using the radioactive, non-hydrolysable GTP 
analogue, [35S]GTPγS [8]. Recently, a novel TRF method, 
which exploits the unique fluorescence properties of 
lanthanide chelates and provides a powerful alternative to 
assays using radioisotopes, has been developed [9]. This new 
assay allows examining GPCR activation by monitoring the 
binding of a non-hydrolysable europium-labeled GTP, GTP-
Eu [10]. This GTP-Eu is incubated with cell membranes. 
When an agonist binds to a GPCR, the GTP-Eu binds to the 
Gα-subunit. After incubation, the unbound GTP-Eu is 
washed away and the signal from the GTP-Eu bound to 
GPCRs is measured using a TRF reader (Fig. 1). In 
particular, GTP-Eu labeled is able to emit a fluorescence 
signal at 615 nm after excitation at 340 nm. This fluorescence 
signal, measured by florescence detector, can be used to 
construct specific dose-response curves of each agonist 
tested because the increase of agonist concentration produces 
an increase of fluorescence signal. On the other hand, the 
study of antagonists is possible too, in fact, in presence of 
them there is a shift of the dose-response curves of agonists. 
This assay is then a valid and powerful alternative to 
traditional radioactive assay and it is a very sensitive tool 
since it is possible to work using small quantity of 
membranes and reagents. Nevertheless, the set-up of this 
assay is an elaborated operation since it requires the 
standardization of the membrane quantity for each receptor, 
the different buffer components, and the incubation time. 
2.2. Fluorescence Polarization Assay 
 This homogeneous method allows rapid and quantitative 
analysis of diverse molecular interactions and enzyme 
activities. This system measures the change in the rotational 
speed of a fluorescent-labeled ligand once it is bound to the 
receptor [11]. The principle of fluorescence polarization is 
described in Fig. (2). When a fluorophore, which is 
covalently attached to a small molecule, is excited by 
polarized light, the emanated light is largely depolarized. 
This event is made possible to reorientation of the 
fluorophore during its excited state caused by rapid 
Brownian molecular rotation of the labeled species [12]. 
Depolarization of the emitted light is influenced by the size 
of the ligand, when a small ligand is used, usually with 
molecular weight <1500 Da, there is a great depolarization, 
originated from light rotational speed [11]. Instead, when the 
ligand utilized is of a larger size, the resulting depolarization 
decreases. Once the labeled ligand is bound to a protein with 
high molecular weight, usually >10 kDa, the fluorophore 
reorients to a much smaller degree, due to the significantly 
reduced rotational speed. This assay is currently being used 
for measuring ligand-binding receptors. Furthermore, it is 
possible to know the affinity of an antagonist by measuring 
the decrease in FP signal produced when it is added in the 
medium containing labeled ligand and receptor [13]. There 
are not market available preconstituted kits to study GPCR 
ligand activity through this technique since each receptor 
system needs specific ligands labeled with a fluorophore. 
One of the first approaches to study new ligands using FP is 
attributed to Banks and coworkers who classified FP as a 
suitable detection method for high throughput drug screening 
with respect to speed of analysis, displaceable signal and 
precision [14-15]. This technique has been widely utilized in 
clinical and biomedical settings, including the diagnosis of 
certain diseases and the monitoring of therapeutic drug levels 
in body fluids. Recently FP assay has been denominated a 
powerful high-throughput screening (HTS) to discover small 
molecule drug for an increasing range of target classes [16]. 
Despite its wide applications, this technique has several 
limitations. The most important limit is the level of 
fluorescence. In fact, fluorescence value increases with
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Fig. (1). Principle GTP-EU assay. 
 
 
 
Fig. (2). Scheme depicting the basic principle of fluorescence polarization. 
 
molecular weight, but reaches a plateau level dependent on 
the fluorophore; moreover, if in a library there are fluorescent 
compounds, this can cause artifacts. In addition, the signal 
measured with this technology is a weighted value of free 
and bound ligand. Therefore, saturation curves are accessible 
only after calculation of the corresponding concentrations of 
free and bound ligand [17]. 
2.3. Fluorescence Resonance Energy Transfer Assay 
 Fluorescence resonance energy transfer (FRET), also 
called Förster resonance energy transfer [18], involves a 
molecular donor fluorophore, that, after absorbing photons 
of a certain wavelength exhibits fluorescence in an excited 
electronic state, which transfers its energy to a close 
molecular acceptor chromophore, through non-radioactive 
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dipole–dipole coupling, which will emit a quantum energy 
depending on its characteristic wavelength. FRET is very 
sensitive to small distance changes because the distance 
between the two dipoles and the efficiency of the energy 
transfer is inversely proportional to the sixth power. 
Therefore, the rate of FRET depends on the degree of 
spectral overlay between the donor and the acceptor, the 
quantum yield of the donor, the relative orientation of the 
donor-acceptor transition dipole moments and the distance 
between the donor-acceptor chromophore (Fig. 3). 
 
 
 
Fig. (3). Spectra of donor-acceptor pair. The colored region 
represents the overlap between the fluorescence spectrum of donor 
and absorption spectrum of acceptor. 
 
 In the case of FRET, the excitation of the donor 
fluorophore results not only in donor emission, but in part in 
emission characteristic for the acceptor fluorophore too. It is 
possible to detect and quantify FRET in several ways. 
Another alternative method is to measure the fluorescence 
lifetime of the donor fluorophore in the presence and 
absence of the acceptor chromophore. FRET will cause a 
decrease in excited lifetime of the donor fluorophore. FRET 
is widely applied for a variety of techniques. In particular, it 
is used as a tool for guaranteeing high sensitivity and this 
technology can be combined with microscopy, chromatographic 
assays, flow cytometry and electrophoresis. FRET can be 
used also for improving spectral characteristics of 
fluorescent dye-labeled protein. It is used in combination 
with monoclonal antibodies leading to structural analysis of 
proteins and also in solutions and in biological membranes. 
In addition, the sensitivity of FRET gives the basis for a 
quick set up, robust, and accurate immunoassays and enzyme 
assays [19]. Moreover, FRET could be used to study GPCRs 
and their ligands. Some authors have demonstrated that it is 
possible to determine if ligands are able to activate the 
receptor as full, partial, or inverse agonists [20]. In fact, full 
and partial agonists cause a FRET decreasing of different 
magnitudes, while inverse agonists cause the increasing of 
FRET. Moreover, when an agonist interacts with the receptor 
there is a change in protein conformation. To monitor this 
change it is worthwhile to use site-specific donor and 
acceptor fluorophores introduced by two orthogonal labeling 
chemistries [21]. In addition, depending on the position of 
the labels, it is possible to monitor the activation and the 
signalling of GPCRs both in the purified reconstituted state 
and in intact cells [22]. Some authors have demonstrated the 
presence of dimer and/or oligomer receptors in native tissue 
by FRET [23-25]. Further, specific FRET signals were 
detected with different receptors expressed in cell lines, 
compatible with their oligomeric or dimeric structure in 
these transfected cells using series of fluorescent agonists 
and antagonists. The major advantage of applying FRET for 
structural studies is that, owing to the specific labeling, the 
complexity and the heterogeneity of the system are not 
important because the object under investigation can be 
detected in situ and/or in vivo with little or no interference. 
FRET can be measured on populations of suspended or 
adhered cells and, when this technique is coupled with 
microscopic imaging, using both wide field and confocal 
microscopes, it allows studying subcellular compartments, 
and makes it possible to limit the data acquisition [25]. 
Likewise, it is very important the use of imaging technologies 
with FRET because the analysis of these studies can show 
both the protein functions, including processes ranging from 
gene expression to second-messenger cascades, and 
intercellular signalling. However, one of the most severe 
limits in protein chemistry has been the difficulty in inserting 
site-specific fluorescent labels [27]. 
 
 
 
Fig. (4). Schematic mechanism of energy transfer between two 
molecules. 
 
2.4. Surface Plasmon Resonance  
 The Surface Plasmon Resonance (SPR) is based on 
optical measurements conducted in real time with a time 
resolution from milliseconds to seconds. The SPR effect was 
known for many years, but was interpreted as light-
stimulated, collective oscillations of valence electrons 
(surface plasmons) in thin solid layers, only few years ago 
[7]. Usually, in the practical applications, thin gold layers on 
the surface of a glass support are used. Habitually, a 
glass/gold interface is illuminated through the glass with a 
convergent beam of light that is totally reflected from the 
interface (Fig. 5). Plasmons are stimulated under a specific 
incidence angle (θresonance), and the stimulation is detected 
as an equivalent minimum of light intensity at a specific 
reflection angle, which is quantified with a diode array 
detector. Experiments are conducted with monochromatic p-
polarized infrared light generated by a light emitting diode. 
An important requisite for the sensor surface is its ability to 
immobilize one of the interacting partners without interfering 
with its action. This involves that immobilization should be 
adequately strong so that microfluidic flows do not result in 
loss of material and this should be reproducible in order to 
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conduct experiments under a multiplicity of conditions. 
Another important step is that this binding is reversible, 
allowing to reuse the same sensor chip. 
 
 
 
Fig. (5). Schematic presentation of the optical system to detect SPR 
phenomena. 
 
 SPR represents the best way to study biomolecular 
interactions at interfaces because the detection takes place in 
real-time and forgoes labeling of any of the molecules. It is 
possible to apply this technique to study GPCRs, but 
researchers due to the high hydrophobicity of membrane 
proteins and the great diversity of receptor-stimulating 
ligands have encountered many difficulties. After many 
efforts by researchers, now it is possible to apply this 
technology to study mechanistic aspects of GPCR activation 
by detecting the turnover of G protein caused by an agonist 
[28, 29]. The weak point of SPR is the lack of sensitivity 
when monitoring low molecular weight adsorbates and rate 
limiting factor of mass transport-affecting kinetic analysis. 
3. CELLULAR ASSAYS 
 There are sensitive and specific methods that allow 
quantitative comparisons of pharmacologic properties of 
GPCRs in physiological or pathological settings [30]. 
Conventionally these assays rely on detecting the activation 
of downstream cellular pathways through the subsequent 
production of intracellular second messengers such as 
calcium, cyclic AMP, and inositol phosphate (IP) or 
extracellular-signal-regulated kinase (ERK) phosphorylation 
and β-arrestin recruitment using various signal detection 
techniques. Each of these assay classes will be thoroughly 
discussed in this review. 
3.1. Assays based on Second Messenger Quantification 
 Measurement of intracellular calcium provides valuable 
information on the activation status of GPCRs and ion 
channels. Several kits commercially available allow monitoring 
the intracellular calcium accumulation and most of them uses 
a fluorescent dye able to cross the cell membrane. Once 
inside the cell, the lipophilic blocking groups of the dye are 
cleaved by an esterase, resulting in a negatively charged 
fluorescent dye that stays inside the cell. Its fluorescence is 
greatly enhanced upon binding to calcium (Ca2+). When cells 
are stimulated with agonists, the receptor signals the release 
of intracellular Ca2+, which significantly increases the 
fluorescence of the dye (Fig. 6). 
 The latest generation of kits utilize an extracellular 
masking technology to block the background fluorescence 
and increase the assay's signal window making them 
indicators of choice for characterizing GPCRs pharmacology 
and function. This technology maximizes the fluorescence 
signal from a wide range of cell types by reducing cell wash 
artefacts. 
 
 
 
Fig. (6). Schematic diagram of the fluorescent dye assay employed 
to measure intracellular calcium accumulation. 
 
 There are calcium assay kits, commercially available, 
that utilize the chromogenic complex (λ = 575 nm) formed 
between calcium ions and o-cresolphthalein to provide a 
simple assay in the physiologically important range of Ca2+ 
concentration 0.4-100 mg/dL (0.1-25 mM). The procedure is 
based on Ca2+ ions reacting with o-cresolphthalein complexone 
in an alkaline solution to form an intense violet coloured 
complex, which maximally absorbs at 577 nm. Recent kits 
are supplied with 8-hydroxyquinoline which is added to 
remove interference by magnesium and iron. In this method 
the absorbance of the Ca-o-cresolphthalein complex is 
measured bichromatically at 570/660 nm. The resulting 
increase in absorbance of the reaction mixture is directly 
proportional to the calcium concentration in the sample. The 
procedure is simple and quick, the assay is convenient, 
sensitive, stable and adaptable to high-throughput. Even if 
calcium assays are robust and easily conformable to HTS, 
there are some significant limitations: fluorescent compounds 
can interfere with assay responses; the assay sensitivity 
sometime is not enough to study GPCRs activity in primary 
cells; calcium flux is fast and momentary, and does not allow 
detection of constitutive activity (or inverse agonism).  
 Another possible method is to measure inositol-3-
phosphate (IP3) production directly or indirectly. In the last 
decade have been developed numerous kits based on 
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different technologies to measure IP3 accumulation, as an 
alternative to the traditional radioactive assays that were 
complex to use and not amenable to HTS. Most important 
technologies used are Amplified Luminescent Proximity 
Homogeneous Assay Screen (AlphaScreen), Homogeneous 
Time Resolved Fluorescence (HTRF), and FP [31, 32]. The 
AlphaScreen is a bead-based non-radioactive and homogeneous 
detection technology in which the beads, which function as 
“donor” and “acceptor”, are coated with a layer of hydrogel 
providing functional groups for bioconjugation. When 
acceptor and donor beads are brought into proximity by a 
molecular interaction occurring between the binding partners 
captured on the beads a cascade of chemical reactions is 
initiated to produce a greatly amplified signal. The assay is 
very flexible and sensitive; it allows measuring a broad 
range of affinities, from low-affinity to high-affinity 
interactions (picomolar to millimolar range) that are difficult 
to detect using traditional assays. 
 Since an innovative method to measure IP3 production in 
cultured cells is to directly quantify myo-inositol-1-
phosphate (IP1), which derives from IP3 after a series of 
enzymatic reactions, there are in the market some kits based 
on competitive immunoassays which are able to detect this 
enzymatic reaction product. Receptor activation promotes 
IP1 production in the cells that competes with an IP1 analog 
coupled to a fluorophore (acceptor) for binding to an anti-
IP1 monoclonal antibody labelled with Eu Cryptate (donor). 
The resulting signal is inversely proportional to the 
concentration of IP1 in the sample. Recently these kits 
contemplate the use of lithium chloride (LiCl) and these 
have the advantage that LiCl inhibits the degradation of IP1, 
the final step in the inositol phosphate cascade, allowing it to 
accumulate in the cell, where it can be measured as a 
substitute for IP3 through HTRF [33,34]. This technique 
permits to quantify IP1 both in adherent and in suspension 
cells allowing studying the biological profile of agonists, 
antagonists and inverse agonists. 
 As previously mentioned, accumulation of IP3 can be 
monitored also by FP. Usually, after stimulation with an 
agonist that increase IP3 production, cells are lysed by 
HClO4, and subsequently fluorescent IP3 tracer and the 
binding protein are added. The IP3 deriving from cell lysates 
competes for binding to the IP3 binding protein. Bound IP3 
tracer will "tumble" more slowly in solution, creating a 
polarized signal (high mP). The polarized signal is inversely 
proportional to the amount of IP3 in the cell lysates. The 
importance of this method is based on the facile adoption of 
FP in HTS, a technique that in the last decade gradually 
almost replaced radioligand binding assays for discovery of 
novel antagonist and agonists of GPCRs and determination 
of their binding affinities, leading to a reduction in assay cost 
and health hazards [35, 36]. 
 Another very accurate method to monitor the GPCRs 
activity is to determine the concentration of one of the most 
important intracellular mediators, cAMP. Its concentration in 
cells can be increased upon binding of many ligands to their 
receptors. The most studied pathway consists in the release 
of G protein α subunit following ligand-receptor interaction, 
which in turn activates or inhibits the ATP/cAMP conversion 
function of adenylate cyclase. The cellular cAMP level 
depends on the activity of two groups of enzymes, the 
adenylyl cyclases (AC) that produce cAMP and the 
phosphodiesterases (PDE) that hydrolyze cAMP [37, 38]. 
Increased cAMP levels activate a number of different 
effector proteins, including protein kinase A (PKA) [39], 
hyperpolarization-activated (Ih) channels [40], the guanine–
nucleotide exchange factor Epac [41], and cyclic nucleotide-
gated (CNG) channels [42]. Given this large involvement in 
cell regulation, cAMP quantification has been of 
considerable interest in the exploration of cell physiology 
and dysfunction. There exist assays designed to directly 
determine the cAMP concentration and others that utilize 
enzymes involved in the signalling cascade that leads to the 
production of this second messenger. Most of the assays 
employed that determine the cAMP production are based on 
immuno-technology or on luciferin-luciferase principle. The 
great part of the immunoassays is competitive assays using a 
cryptate-labeled anti-cAMP antibody and labelled cAMP. 
cAMP produced by cells competes with the labeled cAMP 
for binding to the antibody; therefore the signal that rises 
after interaction between the labeled cAMP and the antibody 
even if it is read both in HTRF and in Luminescence or 
Absorbance is inversely proportional to the level of cellular 
cAMP produced (Fig. 8). 
 Luciferin-luciferase based technology uses flexible 
luciferase-based biosensors for real-time detection of 
signalling events in live cells. This type of assay uses a 
modified form of firefly luciferase mutated joining the wild-
type N- and C-termini with a polypeptide or protein domain; 
this creates engineered termini elsewhere within the structure 
[43, 44]. cAMP or cGMP binding or protease cleavage leads 
to a conformational change in the biosensor, which promotes 
large increases in luminescence activity. The intensity of the 
luminescence increase is directly proportional to the amount 
 
 
Fig. (7). Assay principle using the polarized signal to monitor the amount of IP3. 
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of cAMP/cGMP or protease activity (Fig. 9). The assay, easy 
to perform, allows a real-time recognition of signalling 
events in live cells with sensitivity, linearity and specificity. 
The biosensor is sensitive enough to monitor inverse agonist 
activity or Gi-coupled receptor activation in the absence of 
added forskolin, but at the same time possesses a large 
enough dynamic range to monitor very large increases in 
intracellular cAMP concentration. 
 
 
 
Fig. (9). Intracellular biosensors for cAMP, cGMP, and protease 
detection. 
 
 The most used assays that indirectly determine the cAMP 
concentration involve the quantification of PKA. Most of 
them are based on the principle that cAMP stimulates PKA 
holoenzyme activity, decreasing available ATP and leading 
to reduced light production in a coupled luciferase reaction 
[45, 46]. PKA is composed of two regulatory and two 
catalytic subunits. Each catalytic subunit is a serine/ 
threonine protein kinase, which combines, in the absence of 
cAMP, with each regulatory subunit to form the inactive 
PKA holoenzyme. When the cAMP concentration increases, 
cAMP binds to two sites on the regulatory subunits, leading 
to a conformational change that induce a catalytic subunits 
release. The free catalytic subunits becoming active are able 
to catalyse the transfer of the terminal phosphate of ATP to a 
PKA substrate. The decrease in ATP concentration can be 
observed as light output using luciferase in a reaction that 
requires ATP to produce light; therefore, there is a reciprocal 
relationship between cAMP concentration and the light 
output observed, that allows to quantify the activity of the 
ligands under study at the GPCR of interest (Fig. 10). 
 
 
 
Fig. (10). Schematic diagram of cAMP production and principle of 
a luminescence assay using the PKA holoenzyme activity to 
quantify the cAMP concentration. 
 
3.2. Assays based on Involvement of Pathways 
Downstream in the Signal Transduction Cascade 
 Technologies above mentioned had success in many 
cases but they have limitations. They are limited in the 
capacity to screen orphan receptors and for some of these 
technologies responses for many GPCRs such as Gi coupled 
GPCRs are not easy to measure in current assay formats. A 
suitable alternative could be an assay able to detect the 
activation of ERK phosphorylation cascade pathway, which 
results in the phosphorylation of both cytoplasmic and 
nuclear proteins regulating gene transcription. Evidences 
demonstrate that the ERK 1/2 cascade can be activated by 
different GPCRs, and the complex set of signalling pathways 
that are generated by GPCR stimulation converges at ERK 
1/2 (Fig. 11). Hence, this type of assay has the capability to 
measure cellular changes produced by activation of Gs, Gi 
and Gq coupled receptors giving the possibility to use a 
single assay format for screening [47, 48]. 
 Recent high-throughput assays for detection of intracellular 
ERK 1/2 phosphorylation include electrochemiluminesence-
based and infrared based detection systems. Two alternative 
techniques, able to measure activation of ERK 1/2 in high-
 
 
Fig. (8). Schematic representation of the immuno-competitive assay 
useful to study the intracellular cAMP concentration. 
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throughput format and that can be fully automated with 
standard robotics, could be the immuno-sandwich 
luminescence or immuno-sandwich ELISA assays. In the 
first case Donor beads are coated with streptavidin to capture 
a biotinylated antibody. Acceptor beads are coated with 
Protein A to capture the second antibody. In the presence of 
phosphorylated protein, the two antibodies bring the Donor 
and Acceptor beads close together, generating signal. The 
amount of phosphoprotein present in the sample will be 
directly proportional to the quantity of light emission. In the 
case of immuno-sandwich ELISA assay acceptor beads is 
instead coated with a proprietary agent that immobilizes the 
second assay antibody, labeled with a tag (Fig. 12). This 
eliminates potential interference from spiked antibodies and 
results in better sensitivity and larger dynamic range. 
 
 
Fig. (12). Immuno-sandwich assay principle. 
 
 Two relatively new alternative techniques to examine the 
activity of cell surface receptors are based on impedance-
based assay and optical biosensor technologies. Impedance-
based assay technology for cell-based assays measures 
changes in electrical impedance relative to a voltage applied 
to a cell monolayer that occur in each well upon stimulation 
of cell surface receptors. The system is a major breakthrough 
for accurate monitoring of Gαi- and Gαs-coupled GPCRs, as it 
overcomes many of the challenges and limitations found 
with the traditionally available assay formats. When a GPCR 
is activated by a ligand begins a signal transduction pathway 
mechanism that causes the production of intracellular second 
messengers and cellular morphological changes. In fact, 
production of intracellular effectors results in changes in the 
cellular cytoskeleton, which are reflected as changes in the 
flow of current across and between the cells in the 
monolayer (Fig. 13). This change in the flow of current 
around and through cells is represented in a single well by an 
overall change in the impedance within that well [49, 50]. 
This qualitative data can be used to identify the pathway 
through which receptors transduce their signals, and enables 
interpretation of the action mechanism of lead compounds 
unlike traditional technologies, which measure only discrete 
intracellular events, such as Ca2+ flux or cAMP accumulation. 
In addition this technology, based on impedance measurement, 
eliminates the need of labels, such as tags, dyes, or 
specialized reagents. 
 
 
 
Fig. (13). Activation of GPCRs leads to cytoskeletal changes 
measured through electrical impedance changes. 
 
 
Fig. (11). GPCR signalling pathways via ERK 1/2 can be activated by GPCRs, which couple to different G protein subclasses and transduce 
the signal by different pathways. 
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 The cellular morphological changes produced by the 
ligand binding to the cell surface receptors can be detected 
by an optical biosensor technology too [51]. Usually a 
resonant wave-guide grating biosensor is incorporated into 
the microplate well bottom, which is excited by a fluorescent 
or luminescent light source. The ligand binding induces 
dynamic mass redistribution (DMR) within the bottom 
region of the cell monolayer producing changes in local 
index of refraction that are detected by a spectrometer within 
the label-free technology module. The assay plates are 
measured before (the baseline reading) and after (the final 
reading) compound addition [52, 53]. The results are 
represented as shift between final and baseline readings and 
responses are indicated as DMR (Fig. 14). 
 Optical Biosensor-based cell assays offer several advantages 
over conventional methods including the measurement of 
multiple classes of GPCRs simultaneously from a single 
assay, high-throughput screening, real-time analysis, and a 
non invasive methodology to study GPCR activation and 
signalling. In particular, the applications of these new label-
free tools include cell-based receptor-ligand interactions 
particularly useful for orphan receptors. However, significant 
limitations are present, in fact, labels or cell engineering can, 
in some cases, interfere with the detection, the molecular 
interaction, or the cell biology of target receptors, thus 
resulting in false positives [54].  
 There are also functional assays that directly measure 
GPCR activity by detecting the interaction of β-arrestin, a 
protein involved in signal regulation and receptor 
internalization, with the activated GPCRs. The best 
advantage of this technique is based on the principle that β-
arrestin recruitment occurs independently of G-protein 
coupling, hence similar assays offer a powerful and universal 
platform for measuring receptor activation. There are many 
kits available in the market based on luminescence, 
Bioluminescence Energy Transfer (BRET), and Fluorescence 
Resonance Energy Transfer (FRET). The most common kits 
based on luminescence use enzyme fragment complementation 
of β-galactosidase to measure receptor-β-arrestin proximity 
by chemiluminescence. β-arrestin is fused to a deletion 
mutant of β-galactosidase that is catalytically inactive, while 
GPCR is tagged with a fragment derived from the deleted 
sequence of the enzyme. The activation of GPCR stimulates 
the interaction between the fragment bound to the receptor 
and the remaining part of the enzyme fused to β-arrestin [55, 
56]. The complementation of the two enzyme fragments 
results in the formation of an active β-galactosidase enzyme 
and generation of a chemiluminescent signal (Fig. 15A). Kits 
based on BRET usually possess the GPCR tagged with a 
Renilla Luciferase (RLuc), and the β-arrestin tagged with a 
fluorescent protein tag like green-fluorescent protein (GFP) 
or yellow-fluorescent protein (YFP) [57], or vice versa. 
Receptor stimulation activates β-arrestin that gets close to 
the receptor and the light emitted from the RLuc reaction 
excites the GFP, which then emits a detectable signal at a 
higher wavelength (Fig. 15B). Most of the kits using FRET 
technology use an arrestin tagged with a protease while the 
GPCR is fused in C-terminus with a protease cleavage site 
followed by a transcription factor (TF). When the receptor is 
activated by a ligand, the arrestin is recruited and cleaves the 
protease site fused to the C-terminus of the receptor, 
generating a non-native TF. The TF, without additional 
signalling intermediates, enters the nucleus immediately, 
where it can regulate directly the transcription of a β-
lactamase reporter construct, which is measured after the 
addition of a substrate composed by live cells. The receptor 
modulation by an agonist or an antagonist is directly related 
to the ratio obtained from the blue to green fluorescence [58, 
59]. The activation of the receptor gene by the TF allows a 
quantitative measurement of the degree of interaction 
between the specific receptor and the protease tagged β-
arrestin partner (Fig. 15C). 
CONCLUSION 
 The in vitro assays that are used for bringing new drugs 
from the discovery to the market are undergoing a significant 
and rapid change. In particular, in the field of a highly 
validated and novel family of GPCRs, the in vitro assays 
enable the study of potential new drugs and allow obtaining 
relevant information on activity and toxicity. The attention 
for new assays has moved from radiolabeled to florescence 
or chemiluminescence-based assays together with the use of 
 
 
Fig. (14). Activation of GPCRs leads to a dynamic mass redistribution measured trough an optical biosensor technology. 
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homogenous microliter-plate-based platforms. Studies based 
on these techniques are conducted in live cells and enable the 
study of a multiplicity of signalling systems, and can be 
carried out in biological condition in a quantitative manner. 
All the above mentioned assays have advantages and 
disadvantages and still there is not an assay that completely 
can replace in vivo studies also if an accurate in vitro study 
can improve the chances of successful clinical development 
and, at the same time, allows moving towards more rapid 
and efficient processes decreasing the drug development 
cost. The future will probably depend on achieving the 
proper equilibrium between the quantity of drug candidates 
brought into development and their ability to interact with a 
specific target. Early use of computational approaches to 
select the most promising drugs, followed by high 
throughput experimental determinations, allows determining 
the best drug candidates on the base of their high potency, 
selectivity and low toxicity. 
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